Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Michael Lieberman, M.D., Ph.D.

Michael W. Lieberman, M.D., Ph.D.


Michael W. Lieberman, M.D., Ph.D.

Michael W. Lieberman, M.D., Ph.D.

Emeritus Member 
The Methodist Hospital Research Institute
Chair Emeritus, Department of Pathology and Laboratory Medicine
The Methodist Hospital Physician Organization

E-mail: MLieberman@houstonmethodist.org


B.A.   Yale University, New Haven, CT
M.D.   University of Pittsburgh, Pittsburgh, PA
Ph.D.   Biochemistry, Department of Biochemistry, University of Pittsburgh School of Medicine

Postdoctoral Training

Visiting Fellow, Chester Beatty Institute for Cancer Research, Pollards Wood Research Station, Chalfont–St. Giles, Buckinghamshire, England (1971)
Sarah Mellon Scaife Fellow in Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (1969 – 1970)
U.S.P.H.S. Postdoctoral Fellow, Department of Pathology, University of Pittsburgh School of Medicine and Resident in Pathology, Children's Hospital of Pittsburgh (1968 - 1969)
Intern in Pathology, Health Center Hospitals of the University of Pittsburgh (1967 - 1968)



Dr. Michael W. Lieberman is am Emeritus Member of The Methodist Hospital Research Institute. He formerly held the positions of CEO and Director of TMHRI as the Ernest Cockrell, Jr. Distinguished Endowed Chair. He was also chair of the Department of Pathology at The Methodist Hospital, Professor of Pathology at Weill Cornell Medical College of Cornell University, and Professor of Biology and Biochemistry at the University of Houston.

A native of Pittsburgh, Pennsylvania, he is a graduate of Yale University and received his M.D. and Ph.D. degrees from the University of Pittsburgh School of Medicine. Dr. Lieberman’s research has focused on cancer including the repair of DNA damage by carcinogens, gene expression in cancer and the role of glutathione in the protection of cells from carcinogens and environmental agents.

He was a fellow at the Fels Research Institute (Temple University), the Chester Beatty Institute for Cancer Research (UK), and the National Cancer Institute. He served as head of the somatic cell genetics section of the National Institute of Environmental Health Sciences, professor of pathology and biological chemistry at Washington University (St. Louis), chair of the department of pathology at The Fox Chase Cancer Center and adjunct professor of pathology at the University of Pennsylvania. He came to Houston in 1988 as the W.L. Moody, Jr., professor and chair of the department of pathology and professor in the department of molecular and cellular biology at Baylor College of Medicine. He is the founding director of the Baylor Cancer Center and has led the pathology service at The Methodist Hospital since 1988.

Dr. Lieberman has served on and/or chaired study sections for the National Institutes of Health and the American Cancer Society and is a former member of the National Institute of Environmental Health Sciences National Advisory Board (“Council”). He is past president of the American Society for Investigative Pathology and the Association of University Pathologists. He has been honored with the Gold Headed Cane, a life time achievement award, from the American Society for Investigative Pathology.


Habib GM, Shi ZZ, Lieberman MW. (2007) Glutathione protects cells against arsenite-induced toxicity. Free Radic Biol Med 42:191-201.

Chavez J, Young HW, Corry DB, Lieberman MW. (2006) Interactions between leukotriene C4 and interleukin 13 signaling pathways in a mouse model of airway disease. Arch Pathol Lab Med 130:440-6.

Valverde M, Rojas E, Kala SV, Kala G, Lieberman MW. (2006) Survival and cell death in cells constitutively unable to synthesize glutathione. Mutat Res 594:172-80.

Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, Hannink M. (2005) Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. J Biol Chem 280:30091-9.

Giri U, Terry NH, Kala SV, Lieberman MW, Story MD. (2005) Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28). Cancer Chemother Pharmacol 55:511-21.

Cheng HY, Li P, David M, Smithgall TE, Feng L, Lieberman MW. (2004) Arsenic inhibition of the JAK-STAT pathway. Oncogene 23:3603-12.

Kala SV, Kala G, Prater CI, Sartorelli AC, Lieberman MW. (2004) Formation and urinary excretion of arsenic triglutathione and methylarsenic diglutathione. Chem Res Toxicol 17:243-9.